Raymond James Financial Inc. Invests $431,000 in 10x Genomics, Inc. (NASDAQ:TXG)

Raymond James Financial Inc. bought a new stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 30,005 shares of the company's stock, valued at approximately $431,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TXG. Atria Wealth Solutions Inc. boosted its position in shares of 10x Genomics by 9.6% in the fourth quarter. Atria Wealth Solutions Inc. now owns 10,788 shares of the company's stock worth $155,000 after buying an additional 943 shares during the period. Blue Trust Inc. lifted its position in 10x Genomics by 73.1% during the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock worth $44,000 after acquiring an additional 1,299 shares in the last quarter. Sound Income Strategies LLC boosted its holdings in 10x Genomics by 65.2% in the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock worth $48,000 after acquiring an additional 1,330 shares during the period. Signaturefd LLC grew its position in 10x Genomics by 424.6% in the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company's stock valued at $26,000 after acquiring an additional 1,452 shares in the last quarter. Finally, KBC Group NV raised its stake in shares of 10x Genomics by 57.3% during the fourth quarter. KBC Group NV now owns 5,072 shares of the company's stock valued at $73,000 after purchasing an additional 1,847 shares during the period. Institutional investors and hedge funds own 84.68% of the company's stock.

10x Genomics Stock Performance

Shares of TXG traded up $0.16 during midday trading on Tuesday, hitting $9.65. 4,147,777 shares of the stock traded hands, compared to its average volume of 2,337,246. The business's 50 day moving average price is $8.92 and its two-hundred day moving average price is $12.50. The firm has a market capitalization of $1.18 billion, a PE ratio of -6.35 and a beta of 1.94. 10x Genomics, Inc. has a 1-year low of $6.78 and a 1-year high of $28.25.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.09. 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. The firm had revenue of $154.88 million during the quarter, compared to analysts' expectations of $131.91 million. During the same quarter in the prior year, the firm earned ($0.50) EPS. 10x Genomics's quarterly revenue was down 2.3% on a year-over-year basis. As a group, equities research analysts forecast that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on TXG shares. Leerink Partners lowered shares of 10x Genomics from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $25.00 to $12.00 in a report on Thursday, February 13th. Morgan Stanley lowered their target price on 10x Genomics from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. JPMorgan Chase & Co. cut their price target on 10x Genomics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research note on Friday. UBS Group reduced their price target on 10x Genomics from $14.00 to $12.00 and set a "neutral" rating for the company in a report on Tuesday. Finally, Barclays dropped their price objective on 10x Genomics from $15.00 to $12.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $17.65.

Insider Activity at 10x Genomics

In other news, CEO Serge Saxonov sold 5,092 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $56,368.44. Following the completion of the transaction, the chief executive officer now directly owns 879,482 shares in the company, valued at $9,735,865.74. This trade represents a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Benjamin J. Hindson sold 4,573 shares of the business's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the sale, the insider now directly owns 335,324 shares in the company, valued at approximately $3,712,036.68. The trade was a 1.35% decrease in their position. The disclosure for this sale can be found here. 9.39% of the stock is owned by insiders.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.